Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179

OLIG2-expressing tumor stem cells have been shown to drive recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) and patients urgently need specific therapies to target this tumor cell population.

Research

It is more “unbalanced” than you think

Sébastien Malinge PhD Laboratory Head, Translational Genomics in Leukaemia, Senior Research Fellow (University of Western Australia), Adjunct Senior

Research

Melanoma

Melanoma, also known as malignant melanoma, occurs when abnormal skin cells multiply rapidly in an uncontrolled way.

Research

Brain Tumour

Brain tumours are the second most common cancer in children (after leukaemia).

Research

Risk of childhood acute lymphoblastic leukaemia following parental occupational exposure to pesticides

Risk of childhood acute lymphoblastic leukaemia following parental occupational exposure to pesticides.

Research

Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy

To identify links between drug resistance and gene deregulation we used oligonucleotide microarray technology.

Research

Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia

Rearrangement of the mixed-lineage leukemia gene (MLL) is found in 80% of infant acute lymphoblastic leukemia (ALL) and is associated with poor prognosis and re

Research

Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study

Continuous complete clinical remission in T-cell acute lymphoblastic leukemia (T-ALL) is now approaching 80% due to the implementation of aggressive...

Research

Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism

We examined the baseline profile of a panel of T-ALL cell lines to determine factors that contribute to GC resistance without prior drug selection.

People

Timo Lassmann

Feilman Fellow; Head, Precision Health Research and Head, Computational Biology